Short Communication

Tumor-Specific Immunity: The Promise of Cancer Vaccines

Sumedh Mhaske[1], Sohini Saha[2], Shubhangi Jedhe[3]

[1]Resident Intern, Government Medical College and Hospital, Aurangabad (Maharashtra), [2]Undergraduate Medical Student, Institute of Medical Sciences and SUM Hospital, (Siksha 'O' Anusandhan University) Bhubaneshwar (Odisha), [3]Department of Oral Pathology, People's College of Dental Sciences & Research Centre, Bhopal (Madhya Pradesh)

ABSTRACT:

Cancer vaccines are a potentially effective way to improve the effectiveness of cancer immunotherapy. They are designed to elicit tumor-specific cellular immunity by antigen presentation by dendritic cells. Tumor-associated antigens (TAAs) have been given top priority by the National Cancer Institute as targets for cancer vaccines. AIA stands for "Adoptive Immune Activation." This approach involves transferring immune cells that have been activated and expanded outside the body back into the patient to target and eliminate cancer cells. The AIA took into account a number of parameters, including therapeutic efficacy, immunogenicity, carcinogenicity, specificity, expression level, and positive cell rate. The spectrum of cancer vaccines is delved in this paper, which covers their creation, modes of action, clinical uses, and future directions.

KEYWORDS: Cancer, vaccines, dendritic cells, tumor-associated antigens, immunogenicity

Address for correspondence : Dr Shubhangi Jedhe, Department of Oral Pathology, People's College of Dental Sciences & Research Centre, Bhopal-462037, E-mail: shubhangi.oralpathology@gmail.com

Submitted: 25.02.2024, **Accepted:** 26.05.2024, **Published:** 13.06.2024

INTRODUCTION:

Despite advances in cancer treatment modalities, including surgery, chemotherapy, and immunotherapy, cancer remains a significant global health burden1. Cancer vaccines offer a unique approach by harnessing the body's immune system to recognize and eliminate cancer cells[2,3]. This manuscript is intended to discuss the role of cancer vaccines in eliciting tumor-specific immunity and their potential as a promising treatment strategy for various malignancies.

DEVELOPMENT OF CANCER VACCINES:

The development of cancer vaccines involves the identification and selection of Tumor-associated antigens (TAAs), which are proteins expressed by cancer cells and recognized by the immune system as foreign antigens[4]. TAAs are prioritized based on criteria such as their ability to induce a therapeutic immune response, immunogenicity, specificity to cancer cells, and expression levels. Various vaccine platforms, including peptide-based vaccines, dendritic cell vaccines, and viral vector vaccines, have been explored for their potential to stimulate anti-tumor immunity.

MECHANISMS OF ACTION:

Cancer vaccines work by stimulating dendritic cells to present tumor antigens to T cells, initiating an

Access this article online

Quick Response Code:

Website: www.pjsr.org

DOI: doi.org/10.5281/zenodo.11634347

How to cite this article: Mhaske S, Saha S, Jedhe S. Tumor-Specific Immunity: The Promise of Cancer Vaccines. PJSR. 2024;17(1):68e.

immune response specifically targeting cancer cells (Figure 1). This process leads to the activation and expansion of cytotoxic T cells, which recognize and destroy cancer cells expressing the targeted antigens[5]. Additionally, cancer vaccines may induce the production of tumor-specific antibodies and memory T cells, providing long-lasting immunity against cancer recurrence (Figure 2).

Figure 1: Cancer vaccines work by stimulating dendritic cells to present tumor antigens to T cells, initiating an immune response specifically targeting cancer cells.

CLINICAL APPLICATIONS:

Clinical trials evaluating the safety and efficacy of cancer vaccines have shown promising results in various cancer types, including melanoma, prostate cancer, and lung cancer[6]. Peptide-based vaccines targeting specific TAAs, such as melanoma-associated antigens or prostate-specific antigens, have demonstrated anti-tumor immune responses and improved patient outcomes[7]. Dendritic cell vaccines, which involve the ex vivo loading of dendritic cells with tumor antigens, have also shown efficacy in stimulating anti-tumor immunity in clinical trials[8].

FUTURE DIRECTIONS:

The future of cancer vaccines lies in optimizing vaccine formulations, identifying novel TAAs, and exploring combination therapies with other immunomodulatory agents. Personalized cancer vaccines tailored to individual patients' tumor profiles may enhance treatment efficacy and minimize off-target effects. Furthermore, advances in vaccine delivery systems, adjuvants, and immune monitoring techniques will contribute to the development of more effective cancer vaccines.



Figure 2 : Schematic representation of steps of mechanism of action after vaccine administration.

CONCLUSION:

Cancer vaccines represent a promising approach to harnessing tumor-specific immunity and improving cancer treatment outcomes. By targeting TAAs and stimulating anti-tumor immune responses, cancer vaccines have the potential to complement existing treatment modalities and provide long-term control of cancer progression. Continued research and clinical development are essential to unlock the full potential of cancer vaccines and realize their impact on cancer patient care.

REFERENCES:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8. PMID: 30620402.
2. Sa Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23;359 (6382):1355-1360. doi: 10.1126/science.aar 7112. PMID: 29567706.
3. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer. 2006 Mar;6(3):204-16. doi: 10.1038/nrc1815. PMID: 16498443.
4. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737. PMID: 19723653; PMCID: PMC5779623.
5. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. PMID: 26214521; PMCID: PMC4588240.
6. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004. PMID: 23890062; PMCID: PMC3788678.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. PMID: 20818862.
8. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2. PMID: 25837513; PMCID: PMC4549796.